Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial
Chemotherapy-induced nausea and vomiting (CINV) is a common and debilitating adverse event in cancer chemotherapy [1]. Carboplatin (CBDCA), a second-generation platinum analog, is the key drug in the treatment of thoracic cancers [2]. Several international and national antiemetic guidelines have classified CBDCA as moderate-emetic-risk chemotherapy (MEC) [3 –5]. However, owing to the high emetogenic potential of CBDCA among MEC, the latest guidelines recommend a triplet antiemetic regimen consisting of a 5-hydroxytryptamine type-3 receptor antagonist (5-HT3 RA) combined with dexamethasone (DEX) and a neurokinin-1 recepto...
Source: Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Hirotoshi Iihara, Masamichi Iwai, Ryo Morita, Yukiyoshi Fujita, Keiko Ohgino, Takuma Ishihara, Chiemi Hirose, Yasuyuki Suzuki, Ken Masubuchi, Hitoshi Kawazoe, Daisuke Kawae, Kanako Aihara, Satoshi Endo, Koichi Fukunaga, Mizuki Yamazaki, Takuya Tamura, Yu Source Type: research
Challenges in the management of new daily persistent headache at a tertiary headache center-A retrospective real-world evidence study
CONCLUSION: In this study we add real-world evidence to suggest that prophylactic drugs conventionally used for treating chronic migraine and chronic tension-type headache have limited utility for treating NDPH; however, a partial response in 26% of patients using candesartan and 15% of patients using mirtazapine warrants further investigation in randomized double-blinded placebo-controlled trials.PMID:38646979 | DOI:10.1111/head.14715 (Source: Headache)
Source: Headache - April 22, 2024 Category: Neurology Authors: Thor Linnet Marwa Hussein Henrik Winther Schytz Lars Bendtsen Faisal Mohammad Amin Source Type: research
Mirtazapine Monotherapy and Serotonin Syndrome: When ‘Benign’ Interventions Become Hazardous
1. Identify early signs of serotonin syndrome as well as effective therapeutic management to prevent progressive and life-threatening clinical sequelae.2. Recognize the risks of serotonergic agents, even when used as monotherapy, particularly among at-risk populations. (Source: Journal of Pain and Symptom Management)
Source: Journal of Pain and Symptom Management - April 19, 2024 Category: Palliative Care Authors: John Wagner Source Type: research
Effectiveness of Antidepressants in Combination with Psychotherapy
This study reports the remission rates for the 14 most commonly prescribed single antidepressants (amitriptyline, bupropion, citalopram, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, and venlafaxine) and a category named "Other" (other antidepressants/combination of antidepressants). The study used robust LASSO regressions to identify factors that affected remission rate and clinicians' selection of antidepressants. The selection bias in observational data was removed through stratification. We organized the data into 16,770 subgroups, of at le...
Source: Journal of Mental Health Policy and Economics - April 18, 2024 Category: Psychiatry Authors: Farrokh Alemi Tulay G Soylu Mary Cannon Conor McCandless Source Type: research
Structural insights into the unexpected agonism of tetracyclic antidepressants at serotonin receptors 5-HT < sub > 1e < /sub > R and 5-HT < sub > 1F < /sub > R
Sci Adv. 2024 Apr 19;10(16):eadk4855. doi: 10.1126/sciadv.adk4855. Epub 2024 Apr 17.ABSTRACTSerotonin [5-hydroxytryptamine (5-HT)] acts via 13 different receptors in humans. Of these receptor subtypes, all but 5-HT1eR have confirmed roles in native tissue and are validated drug targets. Despite 5-HT1eR's therapeutic potential and plausible druggability, the mechanisms of its activation remain elusive. To illuminate 5-HT1eR's pharmacology in relation to the highly homologous 5-HT1FR, we screened a library of aminergic receptor ligands at both receptors and observe 5-HT1eR/5-HT1FR agonism by multicyclic drugs described as pa...
Source: Adv Data - April 17, 2024 Category: Epidemiology Authors: Gregory Zilberg Alexandra K Parpounas Audrey L Warren Bianca Fiorillo Davide Provasi Marta Filizola Daniel Wacker Source Type: research
